BIOTEST AG (FRA:BIO) Biotest AG: Biotest announces the new Renate & Hans Schleussner Award for scientific research

Transparency directive : regulatory news

15/09/2021 07:00

DGAP-News: Biotest AG / Key word(s): Miscellaneous
Biotest AG: Biotest announces the new Renate & Hans Schleussner Award for scientific research

15.09.2021 / 07:00
The issuer is solely responsible for the content of this announcement.


PRESS RELEASE

Biotest announces the new Renate & Hans Schleussner Award for scientific research

  • Award's aim is promotion of innovative research in the field of therapies with (hyper-) immunoglobulins
  • In memory of the Schleussner family who founded Biotest, the new research award will be named the Renate & Hans Schleussner Award
  • € 50,000 will be awarded for a preclinical or clinical project


Dreieich, 15 September 2021. Biotest announced today that a new scientific award, the Renate & Hans Schleussner Award, which will be available and open for application from now on. The daughter from Renate & Hans, Cathrin Schleussner was a member of the Supervisory Board of "Biotest AG" since 2001 and held the position of Deputy Chairman from 2004 until the takeover by the Chinese "Creat Group" in 2018.

Immunoglobulins are a major component of the immune system. They are a potent natural tool to counteract viral and bacterial infections.

Scientists or clinicians with innovative ideas relevant to the prevention or treatment of viral infections with (hyper-) immunoglobulins are invited to submit their application. Projects should be related to pathology or management of the disease. Applicants must submit an original research contribution to basic or clinical research. Applications are encouraged from both individuals and teams conducting research at hospitals, universities or independent institutions.
Submissions will be evaluated by Biotest and an independent expert jury consisting of the following members: Prof. Martina Sester (Germany), Prof. Emanuele Cozzi (Italy), Prof. Stephen Jolles (U.K.), Prof. Srini Kaveri (France).

Deadline for the submission of a first project concept is January 31st, 2022. Selected awardees will be invited to prepare a full project proposal. Details on how to apply for the award can be found at:
https://www.biotest.com/de/en/company/corporate_social_responsibilit/renate--hans-schleussner-awar.cfm

 

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 1,900 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.

IR contact
Dr Monika Buttkereit
Phone: +49-6103-801-4406
Mail: investor_relations@biotest.de

PR contact
Dirk Neumüller
Phone: +49-6103-801-269
Mail: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.



15.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1233268

 
End of News DGAP News Service

1233268  15.09.2021 

fncls.ssp?fn=show_t_gif&application_id=1233268&application_name=news&site_id=symex


Other stories

25/09/2021 11:50
25/09/2021 06:03
25/09/2021 16:12
25/09/2021 13:22
25/09/2021 12:17
25/09/2021 12:08
25/09/2021 15:36
25/09/2021 19:04
25/09/2021 11:13
25/09/2021 16:20
25/09/2021 15:19
24/09/2021 18:33
25/09/2021 16:57
25/09/2021 10:12
25/09/2021 09:09
25/09/2021 19:11
25/09/2021 17:00
25/09/2021 08:00
24/09/2021 18:47
24/09/2021 11:12
24/09/2021 21:30
25/09/2021 19:03
25/09/2021 14:14
25/09/2021 13:00
24/09/2021 15:37
24/09/2021 21:59
25/09/2021 17:00
25/09/2021 17:36
25/09/2021 19:20
25/09/2021 17:15
24/09/2021 04:01
23/09/2021 19:01
24/09/2021 11:22
24/09/2021 11:45
25/09/2021 13:10
24/09/2021 13:02
25/09/2021 11:19
24/09/2021 18:00